Table 1.
Laboratory data on the day of the first nivolumab dose
| Normal range | ||
|---|---|---|
| Hematological data | ||
| White blood cells | 10,000/µL | 3,900–9,800 |
| Neutrophils | 87.0% | |
| Eosinophils | 0.0% | |
| Basophils | 0.0% | |
| Monophils | 8.0% | |
| Lymphocytes | 5.0% | |
| Red blood cells | 451×104/µL | 410–570×104 |
| Hemoglobin | 15.3 g/dL | 13.4–17.6 |
| Platlets | 28.1×104/µL | 13.0–37.0×104 |
| Immunological data | ||
| TSH | 1.00 µU/mL | 0.50–5.00 |
| Free T4 | 1.56 ng/dL | 0.90–1.70 |
| ACTH | 20.8 µg/mL | 7.2–63.3 |
| Cortisol | 18.8 µg/dL | 7.1–19.6 |
| Biochemistry data | ||
| Total protein | 6.8 g/dL | 6.5–8.5 |
| Albumin | 3.4 g/dL | 3.9–4.9 |
| Total bilirubin | 1.0 mg/dL | 0.2–1.2 |
| AST | 21 U/L | 8–40 |
| ALT | 13 U/L | 8–40 |
| LDH | 184 U/L | 120–250 |
| BUN | 18.9 mg/dL | 8.0–20.0 |
| Creatinine | 0.72 mg/dL | 0.60–1.10 |
| Na | 135 mEq/L | 136–148 |
| K | 3.7 mEq/L | 3.5–5.3 |
| Ca | 9.1 mg/dL | 8.0–10.0 |
| Tumor markers | ||
| CEA | 5.5 ng/mL | <5.0 |
| CA19-9 | 20.7 U/mL | <37.0 |
ACTH, adrenocorticotropic hormone; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Ca, calcium; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; K, potassium; LDH, lactate dehydrogenase; Na, sodium; T4, thyroxine; TSH, thyroid-stimulating hormone.